Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide) suppress food intake and induce weight loss by targeting distinct neural pathways in the brainstem (NTS, AP, LC, VTA) and hypothalamus, rather than solely relying on peripheral vagal signaling.
GLP-1 medications like semaglutide work by directly acting on specific areas of the brain (brainstem and hypothalamus) to reduce hunger and food intake, rather than just sending signals from the gut. This central action is key to their effectiveness in treating obesity.
it is clear that they all ultimately target the brain to suppress food intake... GLP-1R-expressing vagal afferents have been shown to form intraganglionic laminar endings (IGLEs)... such that they are selectively activated by gastric/duodenal stretch and CCK, but unexpectedly, not by exendin-4.
Why this rating
Based on multiple preclinical studies using contemporary neuroscientific techniques (genetic ablation, electrophysiology) in rodent models.
Source
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Mohammed K. Hankir et al. · Pflügers Archiv - European Journal of Physiology · 2024
DOI 10.1007/s00424-024-03047-3
More from this paper
- Activation of the Area Postrema (AP) by GLP-1R agonists induces aversion (nausea) but is not necessary for appetite suppression, which is mediated by other brainstem regions like the Nucleus Tractus Solitarius (NTS).Good
- Bariatric surgery (RYGB, VSG) and GLP-1R agonists share common neural targets in the brainstem (NTS, lPBN, CeA) and hypothalamus, suggesting overlapping mechanisms of action despite different peripheral origins.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →